Last reviewed · How we verify
COPD Inhaler
At a glance
| Generic name | COPD Inhaler |
|---|---|
| Sponsor | Koronis Biomedical Technologies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Mobile Health Self-Management Intervention for Patient With Chronic Obstructive Pulmonary Disease (NA)
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Design, Development and Evaluation of a Digital Health Assistant for Paediatric Asthma
- Respiratory Exercises in Frail Elderly COPD Patients (NA)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- Effect of Telenursing on Oral Health (NA)
- Feasibility Pilot Trial of Med Management in COPD (NA)
- Improving Adherence to COPD Treatments in Primary Care (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COPD Inhaler CI brief — competitive landscape report
- COPD Inhaler updates RSS · CI watch RSS
- Koronis Biomedical Technologies portfolio CI